The Efficacy of Sequential RT After Triple Therapy for uHCC | NCT07052448 | Trialant

The Efficacy of Sequential RT After Triple Therapy for uHCC | NCT07052448 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
sequential radiotherapy after triple therapy		Patients with unresectable hepatocellular carcinoma received sequential radiotherapy after the combination of transcatheter arterial chemoembolization with lenvatinib and anti-PD-1 antibodies	Drug: sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies

Interventions

Name	Type	Description	Arm Group Labels	Other Names
sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies	Drug	sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
OS	overall survival	From date of randomization until the date of date of death from any cause or the most recent follow-up, whichever came first, assessed up to 100 months

Secondary Outcomes

Measure	Description	Time Frame
PFS	progression-free survival	From date of randomization until the date of first documented progression, the date of death from any cause or the date of most recent follow-up, whichever came first, assessed up to 100 months
ORR

Condition Browse Module